Free Trial
OTCMKTS:ORINY

Orion Oyj 7/17/2023 Earnings Report

Orion Oyj logo
$33.01 -0.02 (-0.06%)
As of 09:36 AM Eastern

Orion Oyj EPS Results

Actual EPS
$0.14
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Orion Oyj Revenue Results

Actual Revenue
$315.26 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Orion Oyj Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Orion Oyj's next earnings date is estimated for Friday, July 18, 2025, based on past reporting schedules.

Conference Call Resources

Orion Oyj Earnings Headlines

European Dividend Stocks To Consider In April 2025
Trump’s Bitcoin Reserve is No Accident…
For the first time in history, we have a president who understands crypto's potential to bypass the banking system entirely. And Wall Street's biggest players know it. I've created a blueprint revealing how everyday investors can turn this historic shift into potentially life-changing wealth. Like the 75,000 new millionaires created in the last bull run— only this time with institutional backing.
Orion Group Interim Report January–March 2025
See More Orion Oyj Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Orion Oyj? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Orion Oyj and other key companies, straight to your email.

About Orion Oyj

Orion Oyj (OTCMKTS:ORINY) develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson's disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer. It also offers Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. In addition, the company provides veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; APIs for generic compounds and proprietary products, as well as contract manufacturing services; and markets and sells veterinary drugs manufactured by other international companies. Further, the company has partnership with Propeller Health to connect the Easyhaler(R) product portfolio; and a research collaboration and license agreement with Amneal Pharmaceuticals, Inc. to commercialize Amneal's generic products. Orion Oyj was founded in 1917 and is headquartered in Espoo, Finland.

View Orion Oyj Profile

More Earnings Resources from MarketBeat